NIH Funding Opportunities

Opportunities are posted in the order they are received and may not appear by due date. Please review accordingly.

Sidebar

NIH - Catalyst Award for Early-Stage Investigators (ESIs) Pursuing Research on HIV Comorbidities, Coinfections, and Complications (DP1- Clinical Trial Optional)

This Catalyst Award is intended to support the development of innovative, often risky, approaches to address significant problems in HIV CCCs research in areas of interest to one or more of the participating NIH Institutes. This FOA is not intended to expand the PD/PIs’ current research program, but instead projects should be a new direction that is reflected by new insight or understanding. Catalyzing advances may emanate from the application of innovative approaches and/or from testing creative hypotheses. 

This funding opportunity announcement (FOA) supports research from creative early stage investigators who propose highly innovative, pioneering studies with potential to open new areas of HIV/AIDS research related to coinfections, comorbidities, and complications. Projects should reflect new and novel scientific directions that are distinct from concepts and approaches being pursued in the investigator’s research program or elsewhere. Projects must be consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR). These priorities have been described most recently in NOT-OD-20-018.

PAR-23-024

Open Date (Earliest Submission Date): April 1, 2023
Next available due Date: May 1, 2023


NIDA REI- Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio. The purpose of this FOA is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.

PAR-23-024

Open Date (Earliest Submission Date): October 14, 2022
Due Date: November 14, 2022


NIDA REI- Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA’s research portfolio. The purpose of this FOA is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities.

RFA-DA-23-023

Open Date (Earliest Submission Date): October 14, 2022
Due Date: November 14, 2022


NIDA REI- Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA)?is a part of?NIDA’s Racial Equity Initiative (REI). This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and/or ethnic communities insubstance use, addiction, and related health consequences, including HIV.

RFA-DA-013

Open Date (Earliest Submission Date): October 14, 2022
Due Date: November 14, 2022


NIDA REI- Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA)?is a part of?NIDA’s Racial Equity Initiative (REI).This FOA invites R01 applications to conduct research that will have a major impact in identifying, developing, implementing, or testing strategies to improve outcomes related to substance misuse, with a goal of preventing, reducing, or eliminating disparities in racial and ethnic minority populations in substance use, addiction, and related health consequences, including HIV. Community engaged research can facilitate rapid advances in this scientific area by ensuring relevant research questions with immediate applicability.

RFA-DA-23-032

Open Date (Earliest Submission Date): October 14, 2022
Due Date: November 14, 2022


NIDA REI- Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI) and invites clinical research applications that are exploratory/developmental in nature and seek to parse the complex effects of structural racism and investigate their impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions.

RFA-DA-23-028

Open Date (Earliest Submission Date): October 14, 2022
Due Date: November 14, 2022


NIDA REI- Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)

This Funding Opportunity Announcement (FOA) is a part of NIDA’s Racial Equity Initiative (REI) and invites clinical research applications that are exploratory/developmental in nature and seek to parse the complex effects of structural racism and investigate their impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions.

RFA-DA-23-029

Open Date (Earliest Submission Date): October 14, 2022
Due Date: November 14, 2022


NIDA REI- Coordination Center to Support Racial Equity and Substance Use Disparities Research (U24 Clinical Trial Not Allowed)

The National Institute on Drug Abuse (NIDA) seeks applications for a Coordination Center to create synergy and linkages across projects funded under NIDA's Racial Equity Initiative (REI) funding opportunity announcements. The Center will provide coordination for collaborative products and activities while housing shared resources. In addition, the Center will optimize the impact of individual REI projects by strengthening community-engaged research efforts and supporting the dissemination and usage of research products and innovations.

RFA-DA-23-025

Open Date (Earliest Submission Date): October 15, 2022
Due Date: November 15, 2022


NIH- Expanding Collaborative Implementation Science to Address Social and Structural Determinants of Health and Improve HIV Outcomes (R01 Clinical Trial Required)

Through this Funding Opportunity Announcement (FOA), the National Institute of Mental Health, in partnership with other NIH Institutes, Centers, and Offices, aims to support implementation science research to strengthen the evidence for effective interventions and implementation strategies that target Social and Structural Determinants of Health (SSDoH) and ultimately improve HIV outcomes and reduce inequities. This initiative will support applications that propose hybrid implementation-effectiveness studies that simultaneously test the effectiveness of interventions addressing SSDoH and implementation strategies to facilitate their uptake or adaptation. This initiative is closely aligned with the goals of the Ending the HIV Epidemic (EHE) in the U.S. initiative, coordinated by the Health and Human Services Office of the Assistant Secretary of Health.

RFA-MH-22-190

Application Due: November 18, 2022


NIH- Expanding Collaborative Implementation Science to Address Social and Structural Determinants of Health and Improve HIV Outcomes (R24 Clinical Trial Not Allowed) 

Through this Funding Opportunity Announcement (FOA), the National Institute of Mental Health in partnership with the National Institute on Drug Abuse, and the Office of Research on Women's Health aims to support implementation science research to strengthen the evidence for effective interventions and implementation strategies that target Social and Structural Determinants of Health (SSDoH) and ultimately improve HIV outcomes and reduce inequities. This R24 will support the activities of a Data Coordination and Consultative Hub to provide scientific leadership across a set of funded R01 project teams supported by its companion RFA (RFA-MH-22-190). The companion R01 RFA will support applications that propose hybrid implementation-effectiveness studies that simultaneously test the effectiveness of interventions addressing SSDoH and implementation strategies to facilitate their uptake or adaptation. This initiative is closely aligned with the goals of the Ending the HIV Epidemic (EHE) in the U.S. initiative, coordinated by the Health and Human Services Office of the Assistant Secretary of Health.

RFA-MH-22-191

Application Due: November 18, 2022


NIAID: Transgender People: Immunity, Prevention, and Treatment of HIV and STIs (R21 Clinical Trial Not Allowed)

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).

PAR-22-186

First Available Due Date: December 07, 2022

Expiration Date: December 08, 2024


NIAID - Notice of Special Interest (NOSI): Towards Developing a Cure for HBV in HIV/HBV Co-Infection

The Notice of Special Interest (NOSI) seeks to fill scientific gaps needed to (a) inform HBV cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts; and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a cure in HIV and HBV co-infected individuals.

NOT-AI-22-043

First Available Due Date: September 05, 2022

Expiration Date: May 08, 2025


NIAID- Notice of Special Interest (NOSI): Sustained Release of Antivirals for Treatment or Prevention of HIV or Treatment of Latent TB/HBV (SRATP)

The purpose of this Notice is to encourage new applications to support further development of a diverse and comprehensive portfolio of SR/LA products for prevention and treatment of HIV. SR/LA antiretroviral products will have a minimum window of protection of three (3) months from either a single dosing (injection, oral administration) or continuous dosing regimen (implant, transdermal patch, etc.) to reflect current state of SR/LA drug market for HIV treatment or prevention.

NOT- AI-22-042

First Available due date: September 7, 2022

Expiration Date: May 8, 2025


The role of Epstein Barr virus (EBV) infection in Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection (U01 Clinical Trial Optional)

This funding opportunity announcement (FOA) focuses on the role of EBV infection on Non-Hodgkin Lymphoma (NHL) and Hodgkin disease (HD) development with or without an underlying HIV infection. The goal is to increase our knowledge through mechanistic, epidemiological, or translational studies that examine how EBV promotes NHL or HD initiation, progression, and the resulting disease sequelae and to provide insights into mechanistic differences in the relationship between EBV infection and lymphomagenesis in HIV+ versus HIV- persons. Research project U01s funded through this PAR will form a cooperative group, the Epstein Barr Virus associated Lymphoma Consortium (EALC).

PAR-21-348

Application Due: December 15, 2022

At a Glance